Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × OTHER × talimogene laherparepvec × Clear all

Phase

Status

Completed 8 Unknown 3 Terminated 3 Recruiting 3 Active not recruiting 3 Withdrawn 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Specimen Handling 15 Magnetic Resonance Spectroscopy 14 Cyclophosphamide 10 Cisplatin 7 Biopsy 7 Bevacizumab 7 pembrolizumab 6 Nivolumab 6 Radiosurgery 5 Doxorubicin 5 Capecitabine 5 fludarabine 4 atezolizumab 4 Vincristine 4 S 1 (combination) 4 Prednisone 4 Oxaliplatin 4 Irinotecan 4 Gemcitabine 4 Fluorouracil 4 Etoposide 4 Drug Therapy 4 Cytarabine 4 Carboplatin 4 durvalumab 3 Surveys and Questionnaires 3 Rituximab 3 Radiation 3 Melphalan 3 Leucovorin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡